韓國LG生命科學 LG Life Sciences Ltd
LG集團所屬的LG生命科學株式會社是韓國大型綜合性制藥公司,公司將新藥研發作為公司發展的關鍵戰略,并已經成功研發出世界水平的幾種新藥。LG生命科學秉承LG集團的經營理念,“為顧客創造價值”和“尊重人格的經營”。
北京樂金科技有限公司是LG集團旗下LG生命科學在中國的全資子公司。其前身是LG生命科學于2004年在北京設立的代表處。經過幾年的探索和發展,根據總部的發展戰略部署,2011年1月1日北京代表處成立了法人公司,進行醫藥產品的引進和市場拓展等業務。產品涵蓋藥品、醫療器械、醫學美容、疫苗、診斷試劑和保健六大類。目前已在中國上市的產品有基因工程產品尤得盼?(Eutropin?,重組人生長激素)、阿司伯根?(重組人促紅細胞生成素)、吉速星?(Factive?,吉米沙星原料藥和片劑)、眼科手術耗材Hyal2000?(醫用透明質酸鈉凝膠)、純天然護膚品安特柔系列(ATOverol?)和HCA&CLA抗衰老系列產品。正在注冊中的有長效生長激素、注射美容類玻尿酸系列產品。
LG生命科學將繼續致力于把世界一流的醫藥產品和技術引進到中國,服務于中國人民的健康。
In the process, corporate value is being raised as we strive to attain our goal of being a top-tier pharmaceutical maker in the global market.
Our involvement in pharmaceuticals dates back to 1981, when we
began genetic engineering research as a division of LG Chemical. Since
then, we have focused on the development of synthetic and bioengineered drugs, and we have enjoyed noteworthy success. For example, our quinolone antibiotic FACTIVE? became the first-ever new drug developed in Korea to receive FDA approval in 2003. It is now available in the US market and sales are growing steadily.
The life sciences industry is committed to promoting human health and longevity. This business also
represents unlimited possibilities and potential for growth.
LG Life Sciences is contributing to the improvement of people health and life quality and is firmly
established as the Korean leader of this strategically important industry. In the future, all LG Life
Sciences employees will continue to strive for global prominence while operating as a highly ethical
corporation that has the public trust.